LONDON, Sept. 3, 2015 /PRNewswire/ -- With a population
of more than 1 billion, China is
the world's largest country and therefore also its single largest
potential market for goods and services. In the past ten years,
China has led all major world
economies in the average rate of growth in real GDP, total health
expenditures, and government health expenditures. As an in vitro
diagnostics (IVD) market, China
trails only the populous, developed markets of the United States, western European countries,
and Japan. China represents one of the largest clinical
laboratory markets in the Asia-Pacific region, and the fastest growing
among the top ten IVD country markets.
This report places China and its
IVD market in context with the developing world in terms of
diseases, economic and healthcare system development, and other key
metrics related to health expenditures and diagnostics.
China as an IVD market opportunity
is defined by its standing next to other populous countries with
demonstrated economic promise for over the past decade -
Brazil, Russia and India; collectively with China referred to as "BRIC" nations.
China and its healthcare system
are confronted by challenges shared by less developed countries,
but also burdens common among developed middle-income and affluent
countries such as diabetes, cardiovascular disease, obesity and
diseases of aging.
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY
Exhibit 1-1: Global Map of China
Exhibit 1-2: Industrial Map of China
Table 1-1: BRIC IVD Markets by Country, 2014-2019
Table 1-2: IVD Sales in China by
Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE
DEVELOPING WORLD - CHINA IN
CONTEXT
Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries
(2010/2050) (Niger, Uganda, Pakistan, India, Egypt,
Guatemala, Morocco, Mexico,Brazil, China, Russia, United
States, France,
Japan, World)
Table 2-2: Selected Worldwide Disease Statistics, 2014
Exhibit 2-1: Diabetes Population by Country, 2015
Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg,Netherlands, Norway, Portugal, Spain, Sweden, United
Kingdom, United States,China)
Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total
Deaths, 2015
Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015
Table 2-4: Clinical Lab Counts and Lab Automation Penetration in
BRIC Countries
Exhibit 2-4: Chinese GDP per Capita by Province, 2012
Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014
Table 2-6: Government and Total Health Expenditures in BRIC and
Comparison Countries (United
States, France,
Germany, Italy, Japan,
United Kingdom, Australia, Brazil, South
Africa, Argentina,
South Korea, Vietnam, Poland,Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia)
Table 2-7: Growth Rates of Government and Total Healthcare
Expenditures and Real GDP (BRIC and Comparison Countries;
2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, South
Korea, South Africa,
Australia, Mexico, United
States, Germany,
United Kingdom, France, Japan, Italy)
Table 2-8: Healthcare System Capacities - BRIC and Comparison
Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan,
South Korea, Mexico, Nigeria, Poland, Russia, South
Africa, Thailand,
Turkey, United Kingdom, United States, Vietnam)
Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country,
2014 (United States, Japan, Germany, France, Italy, China,
Spain, United Kingdom, Brazil, Russia, India)
Table 2-10: BRIC IVD Markets by Country, 2014-2019
Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT
ANALYSIS
Exhibit 3-1: Chinese Hospitals by Tier
Exhibit 3-2: Hospital Count by Certification Status, 2014
Exhibit 3-3: Ethnolinguistic Map of China
Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare
Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United
Kingdom, United States,
Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South
Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria)
Exhibit 3-4: Chinese Urban Healthcare Market by National Market
Shares of Province/Direct-Controlled Municipality
Exhibit 3-5: Chinese Rural Healthcare Market by National Market
Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE
Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern
Europe, China, India, Russia, Brazil, Other)
Table 4-1: Total IVD Sales in China, 2014-2024
Exhibit 4-2: Total IVD Sales in China, 2014-2024
Table 4-2: IVD Sales in China by
Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Exhibit 4-3: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Table 4-3: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Exhibit 4-4: IVD Sales in China by
Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Table 4-4: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Exhibit 4-5: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Table 4-5: Immunoassay Sales in China, 2014-2024
Exhibit 4-6: Immunoassay Sales in China, 2014-2024
Table 4-6: Clinical Chemistry Sales in China, 2014-2024
Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024
Table 4-7: Hematology Sales in China, 2014-2024
Exhibit 4-8: Hematology Sales in China, 2014-2024
Table 4-8: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-10: Selected Point of Care/OTC Products Sold in
China
Table 4-9: Molecular Test Sales in China, 2014-2024
Exhibit 4-11: Molecular Test Sales in China, 2014-2024
Table 4-10: Urinalysis Test Sales in China, 2014-2024
Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024
Table 4-11: Other IVD Test Sales in China, 2014-2024
Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA
Table 5-1: Leading Global IVD Companies in China
Table 5-2: Leading Domestic IVD Companies in China
Table 5-3: Leading Chinese IVD Companies
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY
Exhibit 1-1: Global Map of China
Exhibit 1-2: Industrial Map of China
Table 1-1: BRIC IVD Markets by Country, 2014-2019
Table 1-2: IVD Sales in China by
Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE
DEVELOPING WORLD -CHINA IN
CONTEXT
Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries
(2010/2050) (Niger, Uganda, Pakistan, India, Egypt,
Guatemala, Morocco, Mexico, Brazil, China, Russia, United
States, France,
Japan, World)
Table 2-2: Selected Worldwide Disease Statistics, 2014
Exhibit 2-1: Diabetes Population by Country, 2015
Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, United
Kingdom, United States,
China)
Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total
Deaths, 2015
Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015
Table 2-4: Clinical Lab Counts and Lab Automation Penetration in
BRIC Countries
Exhibit 2-4: Chinese GDP per Capita by Province, 2012
Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014
Table 2-6: Government and Total Health Expenditures in BRIC and
Comparison Countries (United
States, France,
Germany, Italy, Japan,
United Kingdom, Australia, Brazil, South
Africa, Argentina,
South Korea, Vietnam, Poland, Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia)
Table 2-7: Growth Rates of Government and Total Healthcare
Expenditures andReal GDP (BRIC and Comparison Countries; 2003-2013)
(China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, South
Korea, South Africa,
Australia, Mexico, United
States, Germany,
United Kingdom, France, Japan, Italy)
Table 2-8: Healthcare System Capacities - BRIC and Comparison
Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan,
South Korea, Mexico, Nigeria, Poland, Russia, South
Africa, Thailand,
Turkey, United Kingdom, United States, Vietnam)
Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country,
2014 (United States, Japan, Germany, France, Italy, China,
Spain, United Kingdom,Brazil,
Russia, India)
Table 2-10: BRIC IVD Markets by Country, 2014-2019
Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT
ANALYSIS
Exhibit 3-1: Chinese Hospitals by Tier
Exhibit 3-2: Hospital Count by Certification Status, 2014
Exhibit 3-3: Ethnolinguistic Map of China
Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare
Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United
Kingdom, United States,
Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South
Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria)
Exhibit 3-4: Chinese Urban Healthcare Market by National Market
Shares of Province/Direct-Controlled Municipality
Exhibit 3-5: Chinese Rural Healthcare Market by National Market
Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE
Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern
Europe, China, India, Russia, Brazil, Other)
Table 4-1: Total IVD Sales in China, 2014-2024
Exhibit 4-2: Total IVD Sales in China, 2014-2024
Table 4-2: IVD Sales in China by
Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Exhibit 4-3: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Table 4-3: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Exhibit 4-4: IVD Sales in China by
Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Table 4-4: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Exhibit 4-5: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Table 4-5: Immunoassay Sales in China, 2014-2024
Exhibit 4-6: Immunoassay Sales in China, 2014-2024
Table 4-6: Clinical Chemistry Sales in China, 2014-2024
Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024
Table 4-7: Hematology Sales in China, 2014-2024
Exhibit 4-8: Hematology Sales in China, 2014-2024
Table 4-8: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-10: Selected Point of Care/OTC Products Sold in
China
Table 4-9: Molecular Test Sales in China, 2014-2024
Exhibit 4-11: Molecular Test Sales in China, 2014-2024
Table 4-10: Urinalysis Test Sales in China, 2014-2024
Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024
Table 4-11: Other IVD Test Sales in China, 2014-2024
Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA
Table 5-1: Leading Global IVD Companies in China
Table 5-2: Leading Domestic IVD Companies in China
Table 5-3: Leading Chinese IVD Companies
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY
Exhibit 1-1: Global Map of China
Exhibit 1-2: Industrial Map of China
Table 1-1: BRIC IVD Markets by Country, 2014-2019
Table 1-2: IVD Sales in China by
Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE
DEVELOPING WORLD -CHINA IN
CONTEXT
Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries
(2010/2050) (Niger, Uganda, Pakistan, India, Egypt,
Guatemala, Morocco, Mexico,Brazil, China, Russia, United
States, France,
Japan, World)
Table 2-2: Selected Worldwide Disease Statistics, 2014
Exhibit 2-1: Diabetes Population by Country, 2015
Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, United
Kingdom, United States,
China)
Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total
Deaths, 2015
Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015
Table 2-4: Clinical Lab Counts and Lab Automation Penetration in
BRIC Countries
Exhibit 2-4: Chinese GDP per Capita by Province, 2012
Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014
Table 2-6: Government and Total Health Expenditures in BRIC and
Comparison Countries (United
States, France,
Germany, Italy, Japan,
United Kingdom,Australia, Brazil,
South Africa, Argentina, South
Korea, Vietnam,
Poland,Turkey, Mexico,
Russia, Nigeria, China, Thailand, India, Indonesia)
Table 2-7: Growth Rates of Government and Total Healthcare
Expenditures and Real GDP (BRIC and Comparison Countries;
2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, SouthKorea, South Africa, Australia, Mexico, United
States, Germany,
United Kingdom, France, Japan, Italy)
Table 2-8: Healthcare System Capacities - BRIC and Comparison
Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy,Japan, South Korea, Mexico, Nigeria, Poland, Russia, South
Africa, Thailand,
Turkey, United Kingdom, United States, Vietnam)
Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country,
2014 (United States, Japan, Germany, France, Italy, China,
Spain, United Kingdom,Brazil,
Russia, India)
Table 2-10: BRIC IVD Markets by Country, 2014-2019
Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT
ANALYSIS
Exhibit 3-1: Chinese Hospitals by Tier
Exhibit 3-2: Hospital Count by Certification Status, 2014
Exhibit 3-3: Ethnolinguistic Map of China
Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare
Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United
Kingdom, United States,
Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South
Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria)
Exhibit 3-4: Chinese Urban Healthcare Market by National Market
Shares of Province/Direct-Controlled Municipality
Exhibit 3-5: Chinese Rural Healthcare Market by National Market
Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE
Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern
Europe, China, India, Russia, Brazil, Other)
Table 4-1: Total IVD Sales in China, 2014-2024
Exhibit 4-2: Total IVD Sales in China, 2014-2024
Table 4-2: IVD Sales in China by
Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Exhibit 4-3: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Table 4-3: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Exhibit 4-4: IVD Sales in China by
Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Table 4-4: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Exhibit 4-5: IVD Sales in China by
Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Table 4-5: Immunoassay Sales in China, 2014-2024
Exhibit 4-6: Immunoassay Sales in China, 2014-2024
Table 4-6: Clinical Chemistry Sales in China, 2014-2024
Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024
Table 4-7: Hematology Sales in China, 2014-2024
Exhibit 4-8: Hematology Sales in China, 2014-2024
Table 4-8: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-10: Selected Point of Care/OTC Products Sold in
China
Table 4-9: Molecular Test Sales in China, 2014-2024
Exhibit 4-11: Molecular Test Sales in China, 2014-2024
Table 4-10: Urinalysis Test Sales in China, 2014-2024
Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024
Table 4-11: Other IVD Test Sales in China, 2014-2024
Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA
Table 5-1: Leading Global IVD Companies in China
Table 5-2: Leading Domestic IVD Companies in China
Table 5-3: Leading Chinese IVD Companies
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY
Exhibit 1-1: Global Map of China
Exhibit 1-2: Industrial Map of China
Table 1-1: BRIC IVD Markets by Country, 2014-2019
Table 1-2: IVD Sales in China
by Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE
DEVELOPING WORLD - CHINA IN
CONTEXT
Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries
(2010/2050) (Niger, Uganda, Pakistan, India, Egypt,
Guatemala, Morocco, Mexico,Brazil, China, Russia, United
States, France,
Japan, World)
Table 2-2: Selected Worldwide Disease Statistics, 2014
Exhibit 2-1: Diabetes Population by Country, 2015
Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, United
Kingdom, United States,China)
Exhibit 2-3: Cardiovascular Disease Death as a Percentage of
Total Deaths, 2015
Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015
Table 2-4: Clinical Lab Counts and Lab Automation Penetration in
BRIC Countries
Exhibit 2-4: Chinese GDP per Capita by Province, 2012
Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014
Table 2-6: Government and Total Health Expenditures in BRIC and
Comparison Countries (United
States, France,
Germany, Italy, Japan,
United Kingdom,Australia, Brazil,
South Africa, Argentina, South
Korea, Vietnam,
Poland, Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia)
Table 2-7: Growth Rates of Government and Total Healthcare
Expenditures andReal GDP (BRIC and Comparison Countries; 2003-2013)
(China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, South
Korea, South Africa,
Australia, Mexico, United
States, Germany,
United Kingdom, France, Japan, Italy)
Table 2-8: Healthcare System Capacities - BRIC and Comparison
Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan,
South Korea, Mexico, Nigeria, Poland, Russia, South
Africa, Thailand,
Turkey, United Kingdom, United States, Vietnam)
Table 2-9: Per Capita IVD Expenditures and IVD Markets by
Country, 2014 (United States,
Japan, Germany, France, Italy, China,
Spain, United Kingdom,Brazil,
Russia, India)
Table 2-10: BRIC IVD Markets by Country, 2014-2019
Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT
ANALYSIS
Exhibit 3-1: Chinese Hospitals by Tier
Exhibit 3-2: Hospital Count by Certification Status, 2014
Exhibit 3-3: Ethnolinguistic Map of China
Table 3-1: Out-Of-Pocket, Other Private and Government
Healthcare Expenditures in BRIC and Comparison Countries (%)
(South Africa, France, United
Kingdom, United States,
Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South
Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria)
Exhibit 3-4: Chinese Urban Healthcare Market by National Market
Shares of Province/Direct-Controlled Municipality
Exhibit 3-5: Chinese Rural Healthcare Market by National Market
Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE
Exhibit 4-1: Global IVD and Clinical Lab Market, 2014
(United States, Western Europe, Japan, Eastern
Europe, China, India, Russia, Brazil, Other)
Table 4-1: Total IVD Sales in China, 2014-2024
Exhibit 4-2: Total IVD Sales in China, 2014-2024
Table 4-2: IVD Sales in China
by Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Exhibit 4-3: IVD Sales in China
by Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Table 4-3: IVD Sales in China
by Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Exhibit 4-4: IVD Sales in China
by Market Segment (Immunoassays, Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Table 4-4: IVD Sales in China
by Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Exhibit 4-5: IVD Sales in China
by Market Segment (Immunoassays,Clinical Chemistry, Hematology,
POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Table 4-5: Immunoassay Sales in China, 2014-2024
Exhibit 4-6: Immunoassay Sales in China, 2014-2024
Table 4-6: Clinical Chemistry Sales in China, 2014-2024
Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024
Table 4-7: Hematology Sales in China, 2014-2024
Exhibit 4-8: Hematology Sales in China, 2014-2024
Table 4-8: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-10: Selected Point of Care/OTC Products Sold in
China
Table 4-9: Molecular Test Sales in China, 2014-2024
Exhibit 4-11: Molecular Test Sales in China, 2014-2024
Table 4-10: Urinalysis Test Sales in China, 2014-2024
Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024
Table 4-11: Other IVD Test Sales in China, 2014-2024
Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA
Table 5-1: Leading Global IVD Companies in China
Table 5-2: Leading Domestic IVD Companies in China
Table 5-3: Leading Chinese IVD Companies
Download the full report:
https://www.reportbuyer.com/product/3187706/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ivd-in-china-300138078.html
SOURCE ReportBuyer